BW 245C is a prostanoid DP-receptor (DP1) agonist used for the treatment of stroke.
BW245C (0.01-1 μM) suppresses TGF-β-induced collagen secretion in a dose-dependent manner in Th2 cells. BW245C (0.01-1 μM) also increases intracellular cAMP in lung fibroblasts . BW245C (0.1-3 μmol/L) dose-dependently increases transendothelial electrical resistance and decreases the FITC-dextran permeability of human umbilical vein endothelial cells. BW245C (0.3 μmol/L) increases the intracellular cAMP level and subsequent PKA activity .
BW245C attenuates functional deficits after stroke. BW245C significantly reverses these conditions that neurologic deficit is significantly augmented, whereas locomotor activity is significantly reduced after stroke in WT mice. BW245C improves CBF during and after stroke. BW245C results in significantly prolonged bleeding compared with the vehicle-treated group . BW245C (0.02, 0.2, and 2.0 mg/kg) in WT mice results in a significant increase in CBF, but this effect of this treatment is absent in DP1?/? mice. BW245C (0.2 mg/kg) injection 1 h after stroke results in a significant decrease in brain infarction in WT mice, whereas the effect of this treatment is not observed in DP1?/? mice. BW 245C (100 nM) does not significantly increase MBP-positive eosinophils in the esophageal epithelium in OVA-sensitized guinea pigs .